Literature DB >> 15517141

[PET/CT in lymphoma patients].

H C Steinert1.   

Abstract

PURPOSE: First results of PET/CT in Hodgkin's disease (HD) and aggressive non-Hodgkin's lymphoma (NHL) are reported. PATIENTS AND METHODS: From March 2001 to August 2004 822 PET/CT were performed at our clinic in lymphoma patients for primary staging, restaging after therapy, and diagnosis of recurrence. For coregistration non contrast-enhanced low-dose CT were used.
RESULTS: Due to the exact anatomic localization of (18)F-FDG accumulating lesions equivocal or false positive PET findings are avoided. In comparison to contrast enhanced CT, PET/CT has a higher sensitivity and specificity in patients with HD and aggressive NHL. Integration of PET/CT in treatment planning of radiation therapy optimizes the field volume.
CONCLUSION: Even in the initial phase of clinical evaluation, PET/CT has proven useful in staging and restaging of lymphoma. The exact anatomic localization of the PET findings is essential for a precise report, for treatment planning of radiation therapy, and for planning surgical biopsy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15517141     DOI: 10.1007/s00117-004-1121-x

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  28 in total

1.  [Simulation of a mediastinal non-Hodgkin lymphoma recurrence by a diffuse thymus hyperplasia in 18F-FDG PET scan].

Authors:  S Glatz; J Kotzerke; F Moog; M Sandherr; H Heimpel; S N Reske
Journal:  Rofo       Date:  1996-09

2.  Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest.

Authors:  M Bangerter; J Kotzerke; M Griesshammer; K Elsner; S N Reske; L Bergmann
Journal:  Acta Oncol       Date:  1999       Impact factor: 4.089

Review 3.  Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation.

Authors:  G J Cook; I Fogelman; M N Maisey
Journal:  Semin Nucl Med       Date:  1996-10       Impact factor: 4.446

4.  Fluorodeoxyglucose uptake in the aortic wall at PET/CT: possible finding for active atherosclerosis.

Authors:  Mitsuaki Tatsumi; Christian Cohade; Yuji Nakamoto; Richard L Wahl
Journal:  Radiology       Date:  2003-10-30       Impact factor: 11.105

5.  Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT?

Authors:  Niklaus G Schaefer; Thomas F Hany; Christian Taverna; Burkhardt Seifert; Katrin D M Stumpe; Gustav K von Schulthess; Gerhard W Goerres
Journal:  Radiology       Date:  2004-07-23       Impact factor: 11.105

Review 6.  PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies.

Authors:  Heiko Schöder; Steven M Larson; Henry W D Yeung
Journal:  J Nucl Med       Date:  2004-01       Impact factor: 10.057

7.  Sacral fractures: a potential pitfall of FDG positron emission tomography.

Authors:  Laura M Fayad; Christian Cohade; Richard L Wahl; Elliot K Fishman
Journal:  AJR Am J Roentgenol       Date:  2003-11       Impact factor: 3.959

8.  Impact of whole-body 18F-FDG PET on staging and managing patients for radiation therapy.

Authors:  Elena V Dizendorf; Brigitta G Baumert; Gustav K von Schulthess; Urs M Lütolf; Hans C Steinert
Journal:  J Nucl Med       Date:  2003-01       Impact factor: 10.057

9.  Brown adipose tissue: a factor to consider in symmetrical tracer uptake in the neck and upper chest region.

Authors:  Thomas F Hany; Esmaiel Gharehpapagh; Ehab M Kamel; Alfred Buck; Jean Himms-Hagen; Gustav K von Schulthess
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-08-08       Impact factor: 9.236

Review 10.  Positron emission tomography imaging in nonmalignant thoracic disorders.

Authors:  Abass Alavi; Naresh Gupta; Jean-Louis Alberini; Marc Hickeson; Lars-Eric Adam; Peeyush Bhargava; Hongming Zhuang
Journal:  Semin Nucl Med       Date:  2002-10       Impact factor: 4.446

View more
  3 in total

1.  Is PET/CT necessary in paediatric oncology? Against.

Authors:  K Hahn; T Pfluger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-08       Impact factor: 9.236

2.  Value of PET/CT versus PET and CT performed as separate investigations in patients with Hodgkin's disease and non-Hodgkin's lymphoma.

Authors:  Christian la Fougère; Walter Hundt; Nicole Bröckel; Thomas Pfluger; Alexander Haug; Bernhard Scher; Marcus Hacker; Klaus Hahn; Maximilan Reiser; Reinhold Tiling
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-21       Impact factor: 9.236

3.  Malaria masquerading as relapse of Hodgkin's lymphoma on contrast enhanced (18)F-fluorodeoxyglucose positron emission tomography/computed tomography: A diagnostic dilemma.

Authors:  Sunil Jeph; Kamia Thakur; Shamim Ahmed Shamim; Ajay Aggarwal
Journal:  Indian J Nucl Med       Date:  2014-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.